Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00667563 |
|
Recruitment Status
:
Completed
First Posted
: April 28, 2008
Results First Posted
: April 11, 2014
Last Update Posted
: February 29, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
RATIONALE: Vaccines made from virus proteins may help the body build an effective immune response to prevent cervical cancer.
PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine and how well it works in preventing cervical cancer in women in India with HIV-1 infection.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cervical Cancer Nonneoplastic Condition Precancerous Condition | Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Genetic: DNA analysis Genetic: polymerase chain reaction Other: cytology specimen collection procedure Procedure: colposcopic biopsy | Phase 1 |
OBJECTIVES:
Primary
- Assess the safety of the Gardasil® quadrivalent human papillomavirus (HPV) (types 6, 11, 16,18) virus-like-particle vaccine with vs without prior exposure to one or more of the HPV types in the vaccine in HIV-positive women in Chennai, India.
- Determine the effect of the vaccine on HIV viral load and CD4+/CD8+ levels in these patients.
- Determine the proportion of these patients who respond serologically to the HPV vaccine and the kinetics of their response.
Secondary
- Determine the prevalence and incidence of cervical intraepithelial neoplasia in these patients.
- Determine the spectrum of cervical HPV types in these patients at baseline, 9 months, and 1 year after vaccination.
OUTLINE: This is a multicenter study.
Patients receive quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) recombinant vaccine intramuscularly on day 0 and once in weeks 8 and 24.
Patients undergo cervical cell, buccal cell, and blood sample collection at baseline and periodically after vaccination for immunologic and virologic studies. Cervical cytology specimens are examined by polymerase chain reaction to detect HPV 6, 11, 16, or 18 DNA, as well as 35 other HPV types. Blood samples are analyzed for CD4+/CD8+ cell count, plasma HIV-1 RNA levels, and serum HPV antibody titers for HPV types 6, 11, 16, and 18. Some plasma samples will be stored for future HPV pseudovirion neutralization assays.
After completion of study therapy, patients are followed periodically for up to 12 months.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 150 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India |
| Study Start Date : | August 2009 |
| Actual Primary Completion Date : | November 2012 |
| Actual Study Completion Date : | November 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Gardasil Vaccination
Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
|
Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
Genetic: DNA analysis
Weeks 0, 2, 10, 26, and 52.
Other Name: HIV viral load test and HPV neutralization assays.
Genetic: polymerase chain reaction
Screening, week 36, and week 52.
Other: cytology specimen collection procedure
Screening, week 36, and week 52.
Procedure: colposcopic biopsy
Screening, week 36, and week 52.
|
- Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0 [ Time Frame: 52 weeks from study entry ]Number of grade 3 or 4 adverse events attributed to vaccine per 100 patients
- Number of Patients With Significant Decrease (at the 0.05 Significance Level) in CD4+ Cell Count [ Time Frame: Screening/Week 0, Weeks 2, 10, 26, and 52. ]Significant decrease (at the 0.05 significance level) in CD4+ cell count to 75% of the baseline level on two or more consecutive tests
- Number of Patients With Detectable HPV Antibodies to HPV 16 at Week 28 [ Time Frame: Week 28 ]Number of participants with detectable HPV antibody to HPV 16 among those with undetectable antibodies to HPV 16 at baseline
- Number of Patients With a Significant Increase in HIV Viral Load [ Time Frame: Screening/week 0, weeks, 2, 10, 26 and 52 ]Number of patients with a significant increase in HIV viral load defined as > 1 log increase in HIV load from baseline on 2 consecutive occasions
- Number of Patients With Detectable Antibodies to HPV-6 [ Time Frame: 28 weeks ]Detectable antibodies to HPV-6 among participant who had undetectable antibodies to HPV-6 at baseline
- Number of Patients With Detectable Antibodies to HPV-11 [ Time Frame: 28 weeks ]Detectable antibodies to HPV-11 among those who had undetectable antibodies to HPV-11 at baseline
- Number of Patients With Detectable Antibodies to HPV-18 [ Time Frame: 28 weeks ]Detectable antibodies to HPV-18 among participants with undetectable antibodies to HPV-18 at baseline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 120 Years (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by western blot before study entry
- HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test
-
Meets 1 of the following criteria:
- Nadir CD4 level of ≤ 350 cells/mm³ and receiving highly active antiretroviral therapy (HAART) for at least 6 months before study entry
- Nadir CD4 level of > 350 cells/mm³ and not receiving HAART at the time of study entry
- No known history of high-grade CIN or cervical cancer
PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- ANC > 750 cells/mm³
- Hemoglobin ≥ 9.0 g/dL
- Platelet count ≥ 100,000/mm³
- Serum creatinine ≤ 3 times upper limit of normal (ULN)
- AST and ALT ≤ 3.0 times ULN
- Conjugated (direct) bilirubin ≤ 2.5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active drug or alcohol use or dependence that would interfere with adherence to study requirements, in the opinion of the site Investigator
- No serious illness requiring systemic treatment and/or hospitalization within the past 45 days
- No allergy to yeast or any of the components of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
-
More than 45 days since prior systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin
- Routine standard of care, including hepatitis B, influenza, and tetanus vaccines are allowed
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00667563
| India | |
| YRG Care | |
| Chennai, India, 600113 | |
| Study Chair: | Joel Palefsky, MD | University of California, San Francisco | |
| Principal Investigator: | N. Kumarasamy, MD | YRG Care |
| Responsible Party: | AIDS Malignancy Consortium |
| ClinicalTrials.gov Identifier: | NCT00667563 History of Changes |
| Other Study ID Numbers: |
AMC-054 U01CA121947 ( U.S. NIH Grant/Contract ) CDR0000593634 ( Other Identifier: NCI ) |
| First Posted: | April 28, 2008 Key Record Dates |
| Results First Posted: | April 11, 2014 |
| Last Update Posted: | February 29, 2016 |
| Last Verified: | February 2016 |
Keywords provided by AIDS Malignancy Consortium:
|
human papilloma virus infection cervical cancer cervical intraepithelial neoplasia HIV infection |
Additional relevant MeSH terms:
|
Disease Uterine Cervical Neoplasms Precancerous Conditions Pathologic Processes Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site |
Neoplasms Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Vaccines Immunologic Factors Physiological Effects of Drugs |